Walgreens Boots (WBA) profits up 6.4% in Q4 as sales surge

October 14, 2021 03:19 PM PDT | By Sanjeeb Baruah
Follow us on Google News:

Highlights

  • Walgreens’ fourth-quarter sales increased by 12.8% to US$34.3 billion from the year-ago quarter, driven by strong growth in international and the US markets.

  • Walgreens’ net earnings from operations increased by 6.4% YoY to US$358 million in the quarter.

  • Its full-year EPS from continuing operations was US$2.30 against US$0.20 in the year-ago period. The adjusted EPS jumped 14.6% to US$4.91.

Pharmacy chain operator Walgreens Boots Alliance Reports on Thursday reported a fourth-quarter profit of US$358 million after witnessing robust growth in the US and the UK markets.

Walgreens’ net earnings from operations increased by 6.4% YoY to US$358 million in the quarter. Walgreens Boots CEO Roz Brewer said the lifting of Covid-19 restrictions helped in business growth.

He lauded the team members for their stellar performance during the quarter while underscoring the important role of the “pharmacist and local pharmacy” in the ever-changing healthcare sector.

Fourth quarter highlights

Walgreens’ fourth-quarter sales increased by 12.8% to US$34.3 billion from the year-ago quarter, driven by strong growth in its international and the US segments.

The operating income rose by 49.7% YoY to US$910 million in the quarter. In addition, the adjusted operating income from operations jumped 22.9% on a reported currency basis to US$1.2 billion, suggesting strong gross profit growth across pharmacy and retail segments.

Its adjusted net earnings from continuing operations soared 29.6% YoY to US$1.0 billion.

The fourth-quarter EPS from continuing operations were US$0.41, up 6.4% YoY.

Also Read: Citigroup net income jumps 48%, revenue declines 1%

Fiscal 2021 highlights

Its full-year EPS from continuing operations was US$2.30 against US$0.20 in the year-ago period. The adjusted EPS jumped 14.6% to US$4.91.

The total sales for the fiscal year from continuing operations were US$132.5 billion, up 8.6% YoY.

In addition, net cash from operating activities in FY21 rose by US$70 million to US$5.6 billion. Walgreens’ free cash flow increased by US$65 million year-over-year to US$4.2 billion.

Also Read: Domino's Pizza (DPZ) profit jumps 21.5% in Q3 on strong global sales

Walgreens’ fourth-quarter sales increased by 12.8% to US$34.3 billion from the year-ago quarter, driven by strong growth in its international and the US segments.

Source: Pixabay

Also Read: Wells Fargo (WFC), Morgan Stanley (MS) Q3 profits beat estimates

Recent Developments

Walgreens Boots announced a majority investment in healthcare company CareCentrix to boost its technology-enabled homecare capabilities.

Walgreens will invest US$330 million for a 55% stake in CareCentrix, with an option to purchase the remaining portion in the future.

The transaction is expected to close in the second quarter of FY22 after regulatory clearances.

Walgreens has also invested US$5.2 billion in VillageMD to boost its primary healthcare segment in the US. The investment increases Walgreens’ stake in the company to 63%.

Also Read: Bank of America’s (BAC) Q3 profits beat forecast, deposits up 15%  

Stock performance

The Walgreens stock traded at US$51.5499, up 9.08%, at 2:23 pm ET from the previous close.

Its 52-week highest and the lowest stock prices were US$57.05 and US$33.36, respectively, while its P/E and forward P/E one-year ratios are 19.51 and 9.91, respectively.

Walgreens’ market cap is US$44.56 billion, and the annualized Dividend is US$1.91.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.



Top Listed Companies